Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Risk adjusted net present value: What is the current valuation of Pyxis Oncology's PYX-201?
PYX-201 is a monoclonal antibody conjugated commercialized by Pyxis Oncology, with a leading Phase I program in Thyroid Cancer. According...
PYX-201 by Pyxis Oncology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Head And Neck Squamous Cell Carcinoma...
PYX-201 by Pyxis Oncology for Ovarian Cancer: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase...
PYX-201 by Pyxis Oncology for Metastatic Breast Cancer: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Metastatic Breast Cancer. According to GlobalData,...
PYX-201 by Pyxis Oncology for Hepatocellular Carcinoma: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Hepatocellular Carcinoma. According to GlobalData, Phase...
PYX-201 by Pyxis Oncology for Solid Tumor: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Solid Tumor. According to GlobalData, Phase...
PYX-201 by Pyxis Oncology for Kidney Cancer (Renal Cell Cancer): Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Kidney Cancer (Renal Cell Cancer). According...
PYX-201 by Pyxis Oncology for Non-Small Cell Lung Cancer: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Non-Small Cell Lung Cancer. According to...
PYX-201 by Pyxis Oncology for Thyroid Cancer: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Thyroid Cancer. According to GlobalData, Phase...
PYX-201 by Pyxis Oncology for Soft Tissue Sarcoma: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Soft Tissue Sarcoma. According to GlobalData,...
PYX-201 by Pyxis Oncology for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData,...
PYX-201 by Pyxis Oncology for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to...
PYX-201 by Pyxis Oncology for Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer): Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Human Epidermal Growth Factor Receptor 2...
PYX-201 by Pyxis Oncology for Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer): Likelihood of Approval
PYX-201 is under clinical development by Pyxis Oncology and currently in Phase I for Human Epidermal Growth Factor Receptor 2...